文献速递腹部CT

胰腺癌患者接受新辅助或姑息性FOLFIRINOX治疗后转化手术的预测因素:基于基线和随访CT

Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT.
PubMed 文献 · Abdom Radiol (NY) · 2021-06-03

该回顾性研究纳入189例接受超过4周期FOLFIRINOX的胰腺腺癌患者,通过基线、首次随访及术前/末次随访CT评估肿瘤大小变化、胰腺外神经侵犯及可切除性。结果显示基线可切除、首次随访CT部分缓解及基线交界可切除是转化手术的重要预测因素,肿瘤缩小cut-off为22.2%时AUC为0.761。

要点

  • 基线交界可切除、末次CT可切除状态及首次随访CT部分缓解是转化手术的重要预测因素。
  • 肿瘤缩小cut-off为22.2%时,预测转化手术的AUC为0.761,敏感度70.3%,特异度74.8%。
  • 局部晚期亚组中,首次随访CT部分缓解预测转化手术的AUC为0.914,敏感度100%,特异度75%。

核心结论

  • 基线和随访CT表现均有助于预测胰腺腺癌患者接受FOLFIRINOX后的转化手术。

研究设计与样本

  • 回顾性纳入189例接受超过4周期FOLFIRINOX的胰腺腺癌患者,复习基线CT、首次随访CT及术前或末次随访CT,依据RECIST 1.1评估肿瘤大小变化,评估胰腺外神经侵犯及NCCN 2019指南可切除性,并按基线可切除性进行亚组分析。

诊断标准与关键数值

  • 末次CT可切除状态预测手术的HR为65.5(95%CI 5.0-865,P=0.002)。
  • 首次随访CT RECIST部分缓解预测手术的HR为3.6(95%CI 1.1-11.7,P=0.032)。
  • 基线交界可切除预测手术的HR为8.6(95%CI 1.6-46.4,P=0.013)。
  • 肿瘤缩小cut-off为22.2%时,预测手术的AUC为0.761,敏感度70.3%,特异度74.8%。
  • 局部晚期亚组中,首次随访CT部分缓解预测手术的HR为32(95%CI 4.5-227,P=0.001),最佳cut-off为22.2%,AUC为0.914,敏感度100%,特异度75%。

临床应用与阅片要点

  • 基线可切除性、首次随访CT的RECIST部分缓解及末次CT可切除状态可用于预测转化手术可能。
  • 局部晚期患者中,首次随访CT部分缓解对转化手术有较高预测价值。
  • 基线肿瘤大小≥4 cm(HR 5.6,95%CI 1.3-24.3,P=0.022)及首次随访CT不可切除状态(HR 4.8,95%CI 1.1-20.6,P=0.035)与切缘阳性切除显著相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: We aimed to evaluate the predictive factors of conversion surgery in pancreatic adenocarcinoma (PAC) after neoadjuvant or palliative FOLFIRINOX using baseline and follow-up CT.

METHODS: We retrospectively included 189 patients who had undergone more than 4 cycles of FOLFIRINOX. We reviewed baseline CT (B-CT), 1st follow-up CT (1st-CT), and the preoperative or last follow-up CT (L-CT) and determined tumor size changes according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Extra-pancreatic perineural invasion (EPNI) and resectability using NCCN 2019 guideline were evaluated. Subgroup analysis by baseline resectability was performed.

RESULTS: B-CT included resectable (n = 25, 23.2%), borderline (n = 55, 29.1%), locally advanced (n = 44, 23.3%), and metastatic (n = 65, 34.4%) PAC. Seventy-four patients had undergone surgery (39.2%) with an 83.8% (62/74) R0 resection. For operability, resectable status at L-CT (hazard ratio (HR) 65.5; 95% confidence interval (CI) 5.0-865; P = 0.002), RECIST (partial response) at 1st-CT (HR 3.6; 95% CI 1.1-11.7; P = 0.032), and baseline borderline resectability (HR 8.6; 95% CI 1.6-46.4; P = 0.013) were important predictors. Based on a size reduction cut-off of 22.2%, the area under the receiver operating characteristic (ROC) curve (Az) was 0.761 (sensitivity = 70.3%, specificity = 74.8%). In subgroup analysis, RECIST (partial response) at 1st-CT was a significant predictor of locally advanced PAC (HR 32; 95% CI 4.5-227, P 0.001), and the optimal cut-off was 22.2% (Az = 0.914; sensitivity = 100%, specificity = 75%). Baseline tumor size ([Formula: see text] 4 cm) (HR 5.6, 95% CI 1.3-24.3, P = 0.022) and unresectable status at 1st-CT (HR 4.8, 95% CI 1.1-20.6, P = 0.035) were significantly associated with margin-positive resection.

CONCLUSION: Both baseline and follow-up CT findings are useful to predict conversion surgery for PAC after FOLFIRINOX.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Park SJ, Kim JH, Joo I, et al. Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT. Abdom Radiol (NY). 2021. PMID: 34085090. doi:10.1007/s00261-021-03127-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。